Nellore Capital Management LLC Has $8.94 Million Stock Holdings in Enfusion, Inc. (NYSE:ENFN)

Nellore Capital Management LLC reduced its stake in shares of Enfusion, Inc. (NYSE:ENFN) by 58.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 868,085 shares of the company’s stock after selling 1,208,883 shares during the period. Enfusion makes up approximately 1.2% of Nellore Capital Management LLC’s holdings, making the stock its 12th biggest holding. Nellore Capital Management LLC’s holdings in Enfusion were worth $8,941,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new stake in shares of Enfusion during the fourth quarter worth $75,000. Millennium Management LLC acquired a new position in Enfusion in the 4th quarter worth $114,000. Dark Forest Capital Management LP bought a new position in Enfusion during the 4th quarter worth about $128,000. Tower Research Capital LLC TRC increased its holdings in Enfusion by 58.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company’s stock worth $136,000 after purchasing an additional 4,889 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of Enfusion in the 4th quarter valued at about $144,000. Institutional investors own 81.05% of the company’s stock.

Enfusion Price Performance

ENFN stock opened at $10.85 on Wednesday. The stock has a market capitalization of $1.40 billion, a P/E ratio of 271.29, a P/E/G ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a fifty-two week low of $7.83 and a fifty-two week high of $11.80. The business has a 50-day moving average of $10.94 and a 200-day moving average of $10.64.

Enfusion (NYSE:ENFN) last announced its quarterly earnings data on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). The business had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. Equities analysts expect that Enfusion, Inc. will post 0.06 EPS for the current year.

Insider Transactions at Enfusion

In other Enfusion news, CFO Bradley Herring sold 4,645 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total transaction of $52,860.10. Following the transaction, the chief financial officer now owns 324,689 shares of the company’s stock, valued at $3,694,960.82. The trade was a 1.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Bronwen Bastone sold 3,126 shares of the stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total value of $35,573.88. Following the completion of the sale, the insider now owns 221,875 shares in the company, valued at approximately $2,524,937.50. This trade represents a 1.39% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,223 shares of company stock worth $754,778 in the last three months. Insiders own 36.44% of the company’s stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.